New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
DexCom completes $22.5mm Series D financing
08 Jan 2007
Executive Summary
DexCom (glucose monitors) grossed $22.5mm with its Series D venture round to new investors Warburg Pincus (which led the round) and the Vertical Group. Also participating in the financing were existing backers Canaan Partners, Federated Kaufmann Fund, RWI Group, St. Paul Venture Capital, and Fog City Fund (an affiliate of St. Paul). Piper Jaffray acted as placement agent.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com